Dry blending of Wuling Powder Veterinary Grade API into directly compressible tablet matrices requires prior particle-size conditioning because the as-received powder may retain an aggregated coarse fraction that increases interparticulate friction and compromises die filling under high-speed rotary press operation. Sieve classification is first performed in accordance with USP <786> or EP 2.9.38; fractions retained above 150 µm are either co-milled through a pin mill or passed through a 0.5 mm conidur screen to reduce the agglomerate load without destroying the native particle morphology. A pre-blend of the API with microcrystalline cellulose or spray-dried lactose monohydrate at a ratio between 1:3 and 1:5 is prepared in a low-shear bin blender operated at 50–80% of nominal capacity for 15 min, then croscarmellose sodium is added and blended for an additional 10 min. Magnesium stearate is introduced last at 0.5–1.0% w/w and blended for 2–5 min because over-lubrication generates a hydrophobic film on the particle surface and retards tablet disintegration and dissolution. Compression is executed on a rotary tablet press fitted with 19.0 × 9.5 mm oval tooling; main compression force is adjusted within 8–24 kN to obtain a crushing strength of 60–120 N when tested according to USP <1217>. Tablet weight variation and content uniformity are monitored using USP <905> acceptance values, while loss on drying is controlled below 2.0% w/w by USP <731> to reduce capping and lamination during decompression. Disintegration is assessed in 900 mL of water at 37 ± 2 °C using USP <701>; if disintegration exceeds 15 min, the disintegrant level or the granulation route must be revisited. Dissolution testing in USP <711> apparatus II at 50 rpm with 900 mL of 0.1 M hydrochloric acid or pH 6.8 phosphate buffer is used to detect over-granulation or excessive lubricant, and the Q value is set during development until an individual monograph is available. The main process failure observed on production lines is segregation of the low-bulk-density API toward the top of the hopper during extended runs; this is corrected by adding a forced feeder with paddle speed synchronized to turret speed and by maintaining hopper fill between 50% and 80%.

The low tapped bulk density and cohesiveness of fine Wuling Powder fractions create a capsule-filling operation that is controlled more by auger speed, tamping pin pressure, and fill target than by theoretical fill volume. Direct filling into hard gelatin capsules is normally limited to powder blends with a Hausner ratio below 1.25 and a compressibility index below 20% when measured by USP <1174> and USP <616>; if the API exceeds these figures, pre-blending with 0.5–1.5% w/w fumed silica and 10–25% w/w pregelatinized starch is performed in a low-shear tumbler. Capsule size 0 or 1 is selected only after calculating tapped density versus fill weight so that the powder bed does not exceed the capsule body rim. Automatic dosator or tamping-pin machines are run at 60,000–120,000 capsules/hour for veterinary production, with fill weight variation sampled every 30 min and evaluated against USP <905>. Moisture is maintained below 3.0% w/w by USP <921> Karl Fischer analysis because higher moisture plasticizes gelatin capsules and causes dimpling or cross-linking on storage. For low-dose formulations below 10 mg active marker per capsule, the API is first triturated with a directly compressible diluent in a 1:9 ratio to avoid content uniformity drift during hopper vibration.

Which Terminal Sterilization Route Is Excluded When Wuling Powder Fractions Contain Heat-Labile Marker Constituents?

Injectable presentations using Wuling Powder Veterinary Grade API are designed either as clear aqueous solutions of the extracted water-soluble fraction or as sterile suspensions of the micronized powder in a vehicle. The first manufacturing decision concerns the thermal stability of the marker constituents; when terminal steam sterilization at 121 °C for 15 min is not supported by forced degradation data, the process is shifted to aseptic filtration through a 0.22 µm membrane or to dry-heat sterilization of the active powder followed by aseptic compounding. Water for injection used for dissolution must meet the conductivity limit of ≤1.3 µS/cm at 25 °C under USP <645> Stage 1, and the bulk solution is held under nitrogen overlay if marker compounds show oxygen-sensitive degradation. Endotoxin control is critical because multi-component natural-source powders can carry high bacterial endotoxin burdens; the batch is sampled before sterile filtration and tested according to USP <85>, with the acceptance limit calculated from K/M and typically supported by a depyrogenation or ultrafiltration step prior to final dilution. For clear solutions, filtration trains are assembled with a 0.45 µm pre-filter followed by a 0.22 µm PVDF or PES sterilizing-grade membrane, and filter integrity is confirmed by diffusion or bubble-point testing both before filling and after filling under EU GMP Annex 1. Filling is conducted in a Grade A laminar-airflow zone with Grade B background, and filled vials or ampoules are inspected for visible particles under USP <790> lighting conditions. Sub-visible particulate matter is controlled by USP <788> Method 1; for small-volume containers the limits are 6,000 particles/container ≥10 µm and 600 particles/container ≥25 µm, while large-volume containers must remain below 25 particles/mL ≥10 µm and 3 particles/mL ≥25 µm. Tonicity is adjusted with sodium chloride or mannitol to 280–320 mOsm/kg, and pH is maintained between 5.0 and 7.5 using citrate or phosphate buffer unless solubility data indicate a narrower stability window. The filled product is terminally sterilized only if the container-closure system and formulation can withstand the chosen cycle; otherwise an aseptic process is locked with media fills and environmental monitoring per 21 CFR Part 211 and EU GMP Annex 1. Sterility is confirmed by direct inoculation into fluid thioglycollate medium and tryptic soy broth incubated for 14 days at 30–35 °C and 20–25 °C according to USP <71>.

Moisture Sorption and Flow Function Behavior in Low-Dose Reconstitutable Oral Powders

Particle size distribution of the Wuling Powder fraction used in reconstitutable oral powders controls both dissolution kinetics after reconstitution and filling accuracy on vertical form-fill-seal equipment. The powder is normally milled to a D90 below 180 µm with sieve confirmation under USP <786>, and the bulk powder is blended with mannitol or sorbitol as a crystalline diluent to reduce hygroscopic clumping. Because the API may contain moisture-sensitive constituents, bulk powder is stored in double polyethylene liners with desiccants when ambient RH exceeds 60%, and moisture content is checked by USP <921> Karl Fischer analysis at the start and end of the filling campaign. Sachet filling is performed on a vertical form-fill-seal machine using a multi-layer foil laminate tested for water vapor barrier per USP <671>; fill weight variation must meet USP <905> uniformity of dosage units, and seal integrity is tested by vacuum decay or dye penetration at defined intervals. For multi-dose reconstituted oral powders, a preservative system is selected and challenged by USP <51> antimicrobial effectiveness testing; if the product is reconstituted with tap water, the formula is buffered to an acidic pH where preservative partitioning into the headspace is minimized. Reconstitution time is controlled by the fine particle fraction, and over-milling is avoided because it increases surface area and accelerates moisture uptake, causing caking in the sachet before dissolution. The main production bottleneck is electrostatic adhesion of the fine API to the forming film during high-speed sachet filling; anti-static grounding of the forming collar and controlled humidification at 40–50% RH are used to maintain line speeds without fill weight drift.

If Wet Granulation Is Selected for Wuling Powder Blends Containing Hygroscopic Excipients

When wet granulation is selected to improve flow and reduce dust, Wuling Powder Veterinary Grade API is granulated in a high-shear mixer with a binder solution such as low-viscosity hypromellose or povidone in purified water or an ethanol-water mixture. The selection of binder concentration between 3–5% w/w and the liquid-to-solid ratio are critical because the botanical powder can absorb water rapidly and shift from a free-flowing wet mass to an adhesive paste within a narrow window, often a change of 2–4% w/w in total moisture. In production-scale high-shear mixers of 600–1,200 L, impeller speed is kept at 80–150 rpm and chopper speed at 1,500–3,000 rpm; over-granulation is detected by a sharp rise in motor torque or by wet mass adhering to the bowl wall, and under-granulation is visible as a high proportion of fine particles that generate poor granule strength. The wet mass is passed through an oscillating granulator with a 1.0–1.5 mm screen, then dried in a fluid-bed dryer with inlet air at 50–70 °C until product temperature reaches 30–40 °C and loss on drying falls below 2.5% w/w by USP <731> or EP 2.2.32. Dried granules are sized again through a 0.8–1.0 mm screen and the sieve distribution is checked under USP <786>; target retention on 60 mesh and 20 mesh is set to balance flow and compressibility. Granule strength and friability are measured by rotating a weighed fraction in a Roche friabilator or by particle attrition tests; high friability contributes to segregation during downstream transfer and should be corrected by increasing binder level. Final granules are either compressed into tablets or filled into sachets, and the same moisture and content uniformity controls described for other solid dosage forms apply.

Feed Premix Carryover, Segregation Potential, and Mixer Performance Validation

In medicated feed premix manufacture, the carrier system for Wuling Powder Veterinary Grade API must match the density and particle size of the active powder to prevent segregation during in-feed dilution. Corn cob meal, calcium carbonate, wheat middlings, or lactose carriers are selected after measuring bulk density and particle size distribution; the active powder is first pre-dispersed into a carrier fraction at a ratio of 1:10 in a ribbon mixer before adding the remaining carrier. Batch homogeneity is validated by sampling at least 10 locations in the mixer and analyzing marker compound content; the coefficient of variation of the active marker should be established during process qualification and kept under the limit specified in the medicated feed quality system under EU Regulation 2019/4 and current good manufacturing practice for medicated feeds in 21 CFR Part 225. Mixing time in a horizontal ribbon mixer is typically 10–20 min after the final ingredient addition, but over-mixing can fracture friable carrier particles and increase electrostatic charge, so the mixing endpoint is fixed by homogeneity data rather than by timer alone. Carryover is a major operational boundary: the fine, low-density API adheres to mixer walls, discharge gates, and pneumatic conveying lines; dry cleaning followed by a validated wash cycle is required before a different medicated premix is produced to avoid cross-contamination. The premix is packaged in multi-wall paper bags with a polyethylene liner, and storage at controlled temperature below 25 °C and relative humidity below 60% is applied to limit caking and microbial growth. If a liquid carrier such as soybean oil is added at 0.5–1.5% w/w as a dust suppressant, it must be sprayed after the dry mixing phase because early addition traps the API inside oil droplets and delays release in the final feed.

Because the water-dispersible fraction of Wuling Powder dissolves more readily than the residual coarse material, aqueous oral solution manufacture begins with an extraction step rather than direct dispersion of the raw powder in purified water. The extraction is conducted in jacketed stainless-steel vessels at 60–80 °C for 1–3 h under continuous agitation, and the extract is cooled to 20–25 °C before clarification through a plate-and-frame filter or a bag filter with a 10 µm retention rating, followed by a 1 µm depth filter and a 0.45 µm membrane filter. The clarified solution is diluted with purified water to final volume, and preservatives, buffers, and tonicity agents are added after pH adjustment to the target range of 4.5–7.0. Sodium benzoate or potassium sorbate at compendial concentrations is typically selected for oral solutions and is challenged by USP <51> or EP 5.1.3 antimicrobial effectiveness testing. Light exposure is controlled by packaging in amber polyethylene terephthalate or glass bottles; photostability data are generated according to VICH GL5 to define the maximum acceptable light exposure during processing and storage. Filtration at the final filling stage is performed through a 0.22 µm or 0.45 µm cartridge to reduce bioburden, but oral solutions are not required to be sterile; a bioburden limit is established in the batch release specification. Filling is performed on an inline volumetric filler with fill volume checks every 15–30 min, and the finished product is tested for pH, assay, related substances, microbial limits, and antimicrobial preservation according to the registered specification. The solubility of the Wuling Powder extract in cold water may decline after refrigeration; therefore, the formula is evaluated for precipitation at 2–8 °C over the intended shelf life, and if precipitation occurs below a defined temperature, the dosing instructions or the formulation buffer must be revised.